Brilacidin Innovation Pharmaceuticals Inc. Phase
Post# of 72440
Innovation Pharmaceuticals Inc.
Phase II
Exploring its lead defensin mimetic candidate, brilacidin, as a treatment for the COVID-19; potential treatment also for otitis media or externa, skin diseases, Middle East respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus